title: Development of cyclosporine A-loaded dry-emulsion formulation using highly purified glycerol monooleate for safe inhalation therapy.
abstract: The main objective of this study was to improve the safety and oxidative stability of glycerol monooleate (GMO)-based dry-emulsion (DE) formulation containing cyclosporine A (CsA) for inhalation therapy. GMO or highly purified GMO (hpGMO) was used as surfactant for the DE formulations (GMO/DE or hpGMO/DE), the toxicological and physicochemical properties of which were characterized with a focus on oxidative stability, in vitro/in vivo toxicity, and dissolution property. Incubation of GMO at oxidation accelerating conditions for 10 days at 60°C resulted in the formation of lipid peroxides as evidenced by increased malondialdehyde (111 μmol/mg); however, hpGMO samples exhibited increase of only 20.7 μmol/mg in malondialdehyde level. No significant acute cytotoxicity was observed in rat alveolar L2 cells exposed to hpGMO (0.28mM), and intratracheal administration of hpGMO powder in rats did not cause an increase of the plasma LDH level. The hpGMO/DE exhibited marked improvement in dissolution behavior of CsA, and stable fine micelles with a mean diameter of 320 nm were formed when suspended in water. A respirable powder formulation of hpGMO/DE (hpGMO/DE-RP) was newly prepared, and its in vitro inhalation property and in vivo efficacy were also evaluated. The hpGMO/DE-RP exhibited high dispersibility in laser diffraction analysis and significantly improved potency to attenuate recruitment of inflammatory cells into airway and thickening of airway wall in an animal model. Thus, the strategic use of hpGMO would improve oxidative stability and local toxicity compared with a GMO-based DE formulation, and its application to RP formulation could be a promising approach for effective inhalation therapy.
authors.affiliation: Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Sato
authors.forename: Kumiko
authors.initials: K
authors.lastname: Ogawa
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Kojo
authors.forename: Yohei
authors.initials: Y
authors.lastname: Kawabata
authors.forename: Takahiro
authors.initials: T
authors.lastname: Mizumoto
authors.forename: Shizuo
authors.initials: S
authors.lastname: Yamada
authors.forename: Satomi
authors.initials: S
authors.lastname: Onoue
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000941:Antigens / Q000008:administration & dosage; D001249:Asthma / Q000188:drug therapy / Q000473:pathology; D002460:Cell Line; D016572:Cyclosporine / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004655:Emulsions; D005989:Glycerides / Q000737:chemistry*; D008297:Male; D010047:Ovalbumin / Q000008:administration & dosage; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012138:Respiratory Therapy; D013501:Surface-Active Agents / Q000737:chemistry*
chemical_list: D000893:Anti-Inflammatory Agents; D000941:Antigens; D004655:Emulsions; D005989:Glycerides; D013501:Surface-Active Agents; D016572:Cyclosporine; D010047:Ovalbumin; C005953:monoolein